NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
XIBROM (bromfenac sodium) by Bausch + Lomb is anti-inflammatory drug (nsaid) that has anti-inflammatory activity. Approved for macular edema, diabetic retinopathy, retinal vein occlusion and 1 more indications. First approved in 2005.
Drug data last refreshed 21h ago
Mechanism of Action
anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of…
Indications (4)
Worked on XIBROM at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.